Viridian Therapeutics Inc (VRDN) — Strategic Asset Allocation Index
Viridian Therapeutics Inc (VRDN) has a Strategic Asset Allocation Index of 0.6% as of June 2023. Strategic assets (PP&E of $1.88 Million plus long-term investments of $-) total $1.88 Million, measured against net assets of $315.86 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check VRDN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Viridian Therapeutics Inc Strategic Asset Allocation Index (2017–2022)
This chart shows how Viridian Therapeutics Inc's Strategic Asset Allocation Index has evolved across 6 annual periods from 2017 to 2022. As of June 2023, the index stands at 0.6%, representing strategic assets of $1.88 Million against net assets of $315.86 Million USD. See VRDN FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Viridian Therapeutics Inc (2017–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Viridian Therapeutics Inc from 2017 to 2022, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see VRDN market cap.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 0.3% | $1.33 Million | $1.33 Million | $- | $395.06 Million | ▲ +0.1 pp |
| 2021 | 0.2% | $375.00K | $375.00K | $- | $187.72 Million | ▼ -0.5 pp |
| 2020 | 0.7% | $787.00K | $787.00K | $- | $120.04 Million | ▼ -2.7 pp |
| 2019 | 3.3% | $523.00K | $523.00K | $- | $15.75 Million | ▲ +1.9 pp |
| 2018 | 1.4% | $727.00K | $727.00K | $- | $51.34 Million | ▼ 0.0 pp |
| 2017 | 1.5% | $563.00K | $563.00K | $- | $38.51 Million | — |